Resistance to targeted cancer therapy

With the many recent advances in the development of targeted cancer therapies, clinicians have more options than ever to treat their patients. However, while tumours are often initially susceptible to therapy, too often resistance develops and tumours relapse, presenting a major cause of cancer patient death.

From mechanistic studies investigating the development of targeted therapy resistance, to those exploring strategies to prevent and target resistant tumours, with this collection, Nature Communications, Communications Medicine, Communications Biology and Scientific Reports invite submissions to improve our understanding and address the issue of resistance of targeted cancer therapy.